Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trials.
F-R LiuX-L WeiW-N FengH-Y ZhaoY ZhangZ-Q WangD-S ZhangF-H WangS YangW PanX TianL MenH WangE LiangC WangD YangY ZhaiM-Z QiuR-H XuPublished in: ESMO open (2024)
APG-1387 45 mg weekly plus toripalimab was well tolerated and is recommended for further study, with preliminary clinical activity observed in study participants with advanced solid tumors.